LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Large Joints and Extremities/Zimmer Touts “Once-In-A-Lifetime” Hip Replacement
Large Joints and Extremities

Zimmer Touts “Once-In-A-Lifetime” Hip Replacement

August 27, 2014 2 min read Premium comments

Advertisement

Zimmer Touts “Once-In-A-Lifetime” Hip Replacement
Forever Hip Campaign / Courtesy: Zimmer Holdings, Inc
Secondary

Zimmer Holdings, Inc. says it has the only laboratory tested hip replacement technology that mimics the number of steps a person will take during their lifetime following hip replacement surgery.

While not exactly a warranty, Zimmer said on August 22, 2014, that it believes its Vivacit-E Vitamin E highly crosslinked polyethylene (HXPE) liner is the “first hip replacement technology to demonstrate a lifetime of wear performance based on new material advancements and unprecedented testing.”

“Forever Hip”

In announcing the launch of a nationwide “Forever Hip” campaign, the company said ongoing laboratory testing of the liners has surpassed more than 34 years of walking activity. The liners, according to the company, continue to demonstrate ultra-low long-term wear properties under typical conditions and reduce one of the leading barriers to long-term hip replacement success. “Based on this extensive research, Vivacit-E Vitamin E HXPE is now the only hip replacement technology laboratory tested to mimic the number of walking steps a patient will typically take during their lifetime following hip replacement surgery.”

“Once-In-A-Lifetime”

“Surgeons can now provide a once in a lifetime hip replacement technology for their most demanding patients, ” said Matt Monaghan, senior vice president of Global Hips and Reconstructive Research for Zimmer. “This industry leading technology can potentially help patients avoid pain and lost time due to re-operation, as well as lessen the economic burdens that can strain patients and hospitals.”

Each year, the company estimates that more than 330, 000 Americans have experienced relief and restored mobility through total hip replacement. As an increasingly large number of these patients receive hip replacements at a younger age, this new technology can be combined with Zimmer’s other technologies to create a high-demand construct for the younger and more active patient.

Not Proven On People

Advertisement

So as not to get the FDA and trial lawyers too wound up, the company cautions that the Vivacit-E Vitamin E HXPE has been “evaluated for 80 million walking cycles of simulated wear testing in ongoing laboratory testing. Results assume a hip replacement patient will have a life expectancy of 34 years following hip replacement surgery and walk up to 2.2 million steps per year. The results of laboratory testing have not been proven to predict actual performance in people.”

Now, how about that warranty?

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy